<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        3-5480-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        TOBI PODHALER 28MG
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TOBRAMYCIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Inhalation use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Inhalation powder, hard capsule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Inhaler
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        11890.7
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="NOVARTIS" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            NOVARTIS
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                             Mylan Pharma GmbH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01GB01 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>- </strong><em>Pharmacotherapeutic group:</em></p><p>TOBI Podhaler contains a medicine called tobramycin which is an antibiotic. This antibiotic belongs to a class called aminoglycosides.</p><p>TOBI Podhaler is a powder for inhalation filled into capsules. TOBI Podhaler capsules for oral inhalation are to be used only with the supplied inhaler (the Podhaler inhaler).</p><p>&nbsp;</p><p><em>- Therapeutic indications:</em></p><p>TOBI Podhaler is used in patients aged six years and older who have cystic fibrosis to treat lung infections caused by a bacterium called Pseudomonas aeruginosa.</p><p>For the best results from this medicine, please use it as this leaflet instructs you</p><p>&nbsp;</p><p><strong>- </strong><em>How TOBI Podhaler works</em></p><p>When you inhale the contents of TOBI Podhaler capsules,</p><p>the antibiotic can get directly into your lungs to</p><p>fight against the bacteria causing the infection and to improve your breathing.</p><p>&nbsp;</p><p><em>What is Pseudomonas aeruginosa?</em></p><p>It is a very common bacterium that infects the lung of nearly everyone with cystic fibrosis at some time during their lives. Some people do not get this infection until later on in their lives, while others get it very young. It is one of the most damaging bacteria for people with cystic fibrosis. If the infection is not properly fought, it will continue to damage your lungs causing further problems to your breathing.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Follow all the doctor&rsquo;s instructions carefully. They may differ from the general information contained in this leaflet.</p><p>&nbsp;</p><p><strong>a. Do not take TOBI&reg; Podhaler</strong>&trade;</p><p>▪ If you are allergic (hypersensitive) to tobramycin, or to any other aminoglycoside antibiotic.</p><p>If this applies to you, tell your doctor without taking TOBI Podhaler.</p><p>If you think you may be allergic, ask your doctor for advice</p><p>&nbsp;</p><p><strong>b. Take special care with TOBI&reg; Podhaler&trade;</strong></p><p>Tell your doctor if you have or if you have ever had any of the following conditions:</p><p>▪ Hearing problems (including noises in the ears and dizziness), or your mother has had hearing problems after taking an aminoglycoside</p><p>▪ Certain gene variants (a change in the gene) related to hearing abnormalities inherited from your mother</p><p>▪ Kidney problems</p><p>▪ Unusual difficulty in breathing with wheezing or</p><p>coughing, chest tightness</p><p>▪ Blood in your sputum (the substance you cough up)</p><p>▪ Muscle weakness that lasts or becomes worse in</p><p>time, a symptom mostly related to conditions such</p><p>as myasthenia or Parkinson&rsquo;s disease.</p><p>If any of these apply to you, tell your doctor (before taking TOBI Podhaler, when applicable).</p><p>Inhaling medicines can cause chest tightness and</p><p>wheezing and this can happen immediately after inhalation with TOBI Podhaler. Your doctor may ask you to use appropriate medicines, before taking TOBI Podhaler.</p><p>&nbsp;</p><p>Inhaling medicines can also cause cough and this can happen with TOBI Podhaler. Talk to your doctor if the cough is persistent and is a burden for you.</p><p>&nbsp;</p><p>If you are taking tobramycin or another aminoglycoside antibiotic by injection, it can sometimes cause hearing loss, dizziness and kidney damage, and can harm an unborn child.</p><p>&nbsp;</p><p><strong>c. Taking other medicines</strong></p><p>You should not take the following medicines while you are taking TOBI Podhaler:</p><p>▪ Furosemide or ethacrynic acid, a diuretic (&ldquo;water</p><p>tablet&rdquo;)</p><p>▪ Urea or mannitol administered into a vein (intravenous)</p><p>▪ Other medicines which may harm your kidneys or hearing.</p><p>If you are taking one or more of the above medicines, discuss with your doctor before you take TOBI Podhaler.</p><p>Tell your doctor or a pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.</p><p>&nbsp;</p><p><strong>d. Older people (65 year and above)</strong></p><p>If you are aged 65 years and older, your doctor may perform additional tests to decide if TOBI Podhaler is right for you.</p><p>&nbsp;</p><p><strong>e. Children and adolescents (6 years and above)</strong></p><p>TOBI Podhaler can be taken by children and adolescents aged 6 years and older. TOBI Podhaler should not be given to children less than 6 years old.</p><p>&nbsp;</p><p><strong>f. Pregnancy and breast-feeding</strong></p><p>It is not known whether inhaling this medicine when you are pregnant causes side effects. If you want to become pregnant or are pregnant, you should talk to your doctor about the possibility of this medicine causing any harm to you or the unborn child.</p><p>When they are given by an injection, tobramycin and other aminoglycoside antibiotics can cause harm to an unborn child, such as deafness.</p><p>If you are breast-feeding your child, you should talk to your doctor before using your medicine.</p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p>&nbsp;</p><p><strong>g. Driving and using machines</strong></p><p>TOBI Podhaler should not affect your ability to drive and use machines.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take TOBI Podhaler exactly as your doctor has told you. You should check with your doctor if you are not sure.</p><p>Caregivers should provide assistance to children</p><p>starting TOBI Podhaler treatment, particularly those aged 10 years or younger, and should continue to supervise them until they are able to use the Podhaler inhaler properly without help.</p><p>Do not swallow the capsules. The contents of TOBI Podhaler capsules have to be taken by inhalation using only the inhaler that is provided in the pack. Each inhaler is used for seven days and then discarded and replaced. No other capsules should be used with the Podhaler inhaler.</p><p>&nbsp;</p><p><strong>How much TOBI Podhaler to take</strong></p><p>The dose is the same for all persons aged 6 years and older: the content of 4 capsules taken by inhalation twice a day (morning and evening).</p><p>&nbsp;</p><p><strong>When to take TOBI Podhaler</strong></p><p>Taking TOBI Podhaler at the same time each day will help you remember when to take your medicine.</p><p>▪ The content of 4 capsules in the morning to be inhaled using the Podhaler inhaler</p><p>▪ The content of 4 capsules in the evening to be inhaled using the Podhaler inhaler.</p><p>You must leave as close as possible to 12 hours between the dose of the morning (content of 4 capsules inhaled) and the dose of the evening (content of 4 capsules inhaled).</p><p>If you are taking several different inhaled treatments and performing therapies for cystic fibrosis, you should take TOBI Podhaler after all of these are done.</p><p>Please check the order of medications with your doctor.</p><p>&nbsp;</p><p><strong>How long to take TOBI Podhaler</strong></p><p>After taking your medicine for 28 days, you then have a 28-day break, where you don&rsquo;t inhale any TOBI Podhaler, before starting another course.</p><p>It is important that you keep using the product twice each day during your 28 days on treatment and that you keep to the 28-day on, 28-day of cycle.</p><p>&nbsp;</p><p>&nbsp;</p><p>Continue taking TOBI Podhaler as your doctor tells you.</p><p>If you have questions about how long to take TOBI Podhaler, talk to your doctor or your pharmacist.</p><p>&nbsp;</p><p><strong>How to take TOBI Podhaler</strong></p><p>See section <strong>7 Instructions for use of TOBI Podhaler</strong></p><p>Follow your doctor&rsquo;s instructions carefully. Do not exceed the recommended dose.</p><p>&nbsp;</p><p><strong>a. If you take more TOBI&reg; Podhaler&trade; than you should</strong></p><p>If you inhale too much TOBI Podhaler, make sure you tell your doctor as soon as possible.</p><p>If TOBI Podhaler capsules are swallowed, tell your doctor as soon as possible.</p><p><strong>b. If you forget to take TOBI&reg; Podhaler&trade;</strong></p><p>If you forget to take TOBI Podhaler and there are at least 6 hours to your next dose, take your dose as soon as you can. Otherwise, wait for your next dose. Do not double the dose to make up for the missed dose.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>As with all medicines, patients treated with TOBI</p><p>Podhaler may experience side effects, although not</p><p>everybody gets them.</p><p><em>Some side effects could be serious</em></p><p>▪ Unusual difficulty in breathing with wheezing or</p><p>coughing and chest tightness (common).</p><p>If you experience any of these, stop taking TOBI</p><p>Podhaler and <strong>tell your doctor straight away</strong>.</p><p>▪ Worsening of your underlying lung disease (very</p><p>common)</p><p>▪ Coughing up blood (very common)</p><p>▪ Decreasing hearing (ringing in the ears is a potential warning sign of hearing loss), noises (such as hissing) in the ears (common).</p><p>If you experience any of these, <strong>tell your doctor</strong></p><p><strong>straight away</strong>.</p><p><em>Some side effects are very common (These side</em></p><p><em>effects may affect more than 1 in 10 patients).</em></p><p>▪ Shortness of breath</p><p>▪ Cough, productive cough, voice alteration (hoarseness)</p><p>▪ Sore throat</p><p>▪ Headache</p><p>▪ Fever</p><p>If any of these affects you severely, <strong>tell your doctor.</strong></p><p><em>Some side effects are common (These side effects</em></p><p><em>may affect between 1 and 10 in every 100 patients</em><strong><em>).</em></strong></p><p>▪ Wheezing, rales (crackles)</p><p>▪ Chest discomfort, chest pain from muscles and/or skeleton origins</p><p>▪ Loss of voice</p><p>▪ Decreased results for the tests of lung function</p><p>▪ High level of sugar (glucose) in the blood</p><p>▪ Blocked nose</p><p>▪ Nosebleed</p><p>▪ Vomiting, nausea</p><p>▪ Diarrhea</p><p>▪ Rash</p><p>▪ Disturbed sense of taste.</p><p>If any of these affects you severely, <strong>tell your doctor.</strong></p><p><em>The frequency of some side effects is not known (The frequency cannot be estimated from the available data)</em></p><p>▪ Generally feeling unwell</p><p>▪ Discoloration of the substance you cough up (sputum).</p><p>If any of these affects you severely, <strong>tell your doctor.</strong></p><p>If you notice any other side effects not mentioned in this leaflet, please inform your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>▪ Do not store above 30&deg;C.</p><p>▪ Store in the original package to protect from moisture.</p><p>▪ Store the inhaler in its tightly closed case when not in use.</p><p>▪ Keep out of the sight and reach of children.</p><p>▪ Do not use Tobi Podhaler after the expiry date</p><p>which is stated on the pack after (EXP.). The expiry date refers to the last day of that month.</p><p>▪ Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a. What TOBI&reg; Podhaler&trade; contains</strong></p><p>▪ The active substance of TOBI Podhaler is tobramycin</p><p>▪ The other ingredients are:</p><p>Powder: DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine), calcium chloride, sulfuric acid.</p><p>Capsule shell: Hypromellose, potassium chloride,</p><p>carrageenan, carnauba wax, blue ink</p><p>This information might differ in some countries</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                TOBI Podhaler is a powder for inhalation (white to 
almost white) filled into clear colorless hypromellose
capsules with “MYL TPH” imprinted in blue ink on
one part of the capsule and the Mylan logo imprint-ed in blue on the other part of the capsule.
Each capsule contains 28 mg tobramycin.
The capsules are inhaled only with the supplied
Podhaler inhaler.
This information might differ in some countries.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><em>Marketing Authorization Holder:</em></p><p>Mylan Pharma GmbH,</p><p>Turmstrasse 24,</p><p>6312 Steinhausen, Switzerland</p><p>Tel. +41 (0)41 768 48 48</p><p>Fax. +41 (0)41 768 48 49</p><p>e-mail: info.ch@mylan.com</p><p>&nbsp;</p><p><em>Manufacturer:</em></p><p>Mylan Pharmaceuticals, Inc.,</p><p>150 Industrial Road, San Carlos,</p><p>CA 94070, USA</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Revision date: This leaflet was last revised in Feb 2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p><strong>&nbsp;</strong></p><p>&trade; &nbsp;- ما هو توبي&reg; بودهيلر</p><p>يحتوي توبي بودهيلر على دواء يُسمَى توبرامايسين وهو مضاد حيوي. هذا المضاد</p><p>الحيوي ينتمي إلى فئة تُسمَى أمينوجلايكوسيد</p><p>توبي بودهيلر هو مسحوق لاستنشاق معبأ في كبسولات. كبسولات توبي بودهيلر</p><p>للاستنشاق بالفم يجب أن تُستخدَم فقط مع البخاخة المُرفقة (بخاخة بودهيلر)</p><p>&trade; - ما هي استعمالات توبي&reg; بودهيلر</p><p>يُستعمَل توبي بودهيلر في مرضى التليف الكيسي الذين يبلغون من العمر 6 سنوات</p><p>فأكثر لعلاج العدوى الرئوية بالبكتريا المسماة سودوموناس إيروجينوزا</p><p>لتحقيق أفضل النتائج من هذا الدواء، برجاء أن تستعمله طبقاً للتعليمات المذكورة</p><p>في هذه النشرة.</p><p>&trade;- كيف يعمل توبي&reg; بودهيلر</p><p>إذا كانت لديك أي أسئلة عن الكيفية التي يعمل بها توبي بودهيلر أو عن سبب</p><p>وصف هذا الدواء لك، برجاء أن تسأل طبيبك</p><p>عندما تستنشق محتويات كبسولات توبي بودهيلر، فإن المضاد الحيوي يصل</p><p>مباشرة إلى رئتيك لمقاومة البكتريا المسببة للعدوى ولتحسين تنفسك</p><p>هو نوع شائع جداً من البكتريا يُصيب الرئة تقريباً في جميع مرضى التليف الكيسي</p><p>في وقت ما من حياتهم. بعض الأشخاص لا يلتقطون هذه العدوى إلا في وقت</p><p>متأخر من حياتهم، بينما البعض الآخر يُصاب بها في سن صغير جداً. وهو من بين</p><p>البكتريا الأكثر ضرراً في مرضى التليف الكيسي. إذا لم تتم مكافحة العدوى بشكل</p><p>صحيح، فإنها تستمر في تدمير رئتيك وتؤدي إلى مزيد من المشاكل في تنفسك</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>&trade;&reg;</strong><strong> بودهيلر</strong><strong> &nbsp;&nbsp;</strong><strong>-2 قبل أن تستعمل توبي</strong></p><p>التزم بجميع تعليمات طبيبك بكل دقة. هذه التعليمات قد تكون مختلفة عن المعلومات</p><p>العامة المذكورة في هذه النشرة</p><p>&nbsp;</p><p><strong>&trade; </strong><strong>&nbsp;توبي&reg; بودهيلر</strong><strong> &nbsp;</strong><strong>ا. </strong><strong>ل</strong><strong>ا تستعمل</strong></p><p>&nbsp;&nbsp;<strong>إذا كانت لديك أرجية </strong>(حساسية مفرطة) تجاه توبرامايسين، أو تجاه أي مضاد</p><p>حيوي آخر من نوع أمينوجلايكوسيد</p><p>إذا انطبق هذاعليك ، <strong>أخبر طبيبك مع الامتناع عن استعمال توبي بودهيلر</strong><strong>.</strong></p><p>إذا ظننت أن لديك أرجية ، استشر طبيبك.</p><p><strong>&trade; </strong><strong>ب. يجب توخي الحذر الخاص مع توبي</strong><strong>&reg;</strong><strong> بودهيلر </strong></p><p>أخبر طبيبك إذا كنت تعاني الآن أو في أي وقت سابق من أي من الحالات التالية:</p><p>&nbsp;&nbsp;-مشاكل في السمع (تشمل حدوث ضوضاء في اأذنين ودوخة) أو إذا</p><p>كانت والدتك تعاني من مشاكل في السمع بعد تناول أمینوجلایكوسید</p><p>- بعض المتغیرات الجینیة (تغییر في الجین) المتعلقة بتشوھات السمع الموروثة من والدتك</p><p>&nbsp;&nbsp;-مشاكل في الكلى</p><p>&nbsp;&nbsp;-صعوبة غير معتادة في التنفس مع أزيز أو سعال ، ضيق في التنفس</p><p>- وجود الدم في البلغم الخاص بك (المادة التي تسعلھا)</p><p>&nbsp;&nbsp;-ضعف عضلي مستمر أو يزداد سوءاً مع مرور الزمن ، وهو أحد الأعراض</p><p>المرتبطة غالباً بحالات مثل الوهن العضلي أو مرض باركنسون</p><p>&nbsp;</p><p>إذا انطبق عليك أي من هذه الأمور، <strong>أخبر طبيبك (قبل أن تستعمل توبي بودهيلر،</strong></p><p>في حالة انطباقها)</p><p>قد يؤدي استنشاق الأدوية إلى حدوث ضيق في التنفس وأزيز وهذا قد يحدث فوراً</p><p>بعد استنشاق توبي بودهيلر. قد يطلب منك طبيبك استعمال الأدوية المناسبة، قبل</p><p>استعمال توبي بودهيلر</p><p>&nbsp;استنشاق بعض الأدویة قد یؤدي إلى السعال ویمكن أن یحدث ھذا مع توبي بودھیلر</p><p>.تحدث إلى طبیبك إذا كان السعال مستمرا وكان عبئًا علیك</p><p>إذا كنت تستعمل توبرامايسين، أو أحد المضادات الحيوية الأخرى من نوع</p><p>أمينوجلايكوسيد عن طريق الحقن، فإنه قد يؤدي أحياناً إلى فقدان السمع، ودوخة،</p><p>وتلف في الكلى، وقد يسبب الأذى للجنين</p><p>&nbsp;</p><p><strong>ج. استعمال أدوية أخرى</strong></p><p>لا ينبغي أن تستعمل اأدوية التالية أثناء استعمال توبي بودهيلر:</p><p>أقراص الماء) &nbsp;&nbsp;)&bull; فيوروسيميد أو حمض إيثاكرينيك، وهو مدر للبول</p><p>يوريا، أو مانيتول بالحقن في الوريد&nbsp;&nbsp; &bull;</p><p>الأدوية الأخرى التي قد تؤذي الكلى أو السمع &bull;</p><p>إذا كنت تستعمل واحداً أو أكثر من الأدوية المذكورة عاليه، ناقش الأمر مع طبيبك</p><p>قبل أن تستعمل توبي بودهيلر</p><p>أخبر طبيبك أو الصيدلي إذا كنت تستعمل حالياً أو إذا كنت قد استعملت منذ فترة</p><p>قصيرة أي أدوية أخرى، ويشمل ذلك الأدوية التي يتم الحصول عليها بدون تذكرة</p><p>طبية</p><p>&nbsp;</p><p><strong>د. الأشخاص الأكبر سناً (</strong><strong>65 </strong><strong>سنة من العمر فأكثر) </strong></p><p>إذا كنت تبلغ من العمر 65 سنة فأكثر، قد يُجري لك طبيبك اختبارات إضافية</p><p>لتحديد ما إذا كان توبي بودهيلر مناسباً لك</p><p>&nbsp;</p><p><strong>ه. الأطفال (تحت </strong><strong>6 </strong><strong>سنوات من العمر) </strong></p><p>يمكن استعمال توبي بودهيلر في الأطفال والمراهقين الذين يبلغون من العمر 6</p><p>سنوات فأكثر. لا ينبغي إعطاء توبي بودهيلر لأطفال تحت 6 سنوات من العمر</p><p>&nbsp;</p><p><strong>و. الحمل والإرضاع</strong></p><p>لا يُعرَف ما إذا كان استنشاق هذا الدواء أثناء الحمل يؤدي إلى حدوث آثار جانبية.</p><p>إذا كنتِ حاملاً أو إذا كنتِ ترغبين في الحمل، يجب أن تتحدثي مع طبيبك بشأن ما</p><p>إذا كان هذا الدواء يمكن أن يسبب أي أذى لكِ أو للجنين</p><p>عند إعطاء توبرامايسين والمضادات الحيوية الأخرى من نوع الأمينوجلايكوسيد</p><p>عن طريق الحقن، فإنه قد يسبب الأذى للجنين، مثلاً في شكل صمم</p><p>إذا كنتِ ترضعين طفلك من الثدي، يجب أن تتحدثي مع طبيبك قبل استعمال دوائك</p><p>استشيري طبيبك أو الصيدلي قبل استعمال أي دواء</p><p>&nbsp;</p><p><strong>س</strong><strong>. </strong><strong>قيادة</strong><strong> </strong><strong>السيارة</strong><strong> </strong><strong>وتشغيل</strong><strong> </strong><strong>الآلات</strong></p><p>من غير المُفترَض أن يؤثر توبي بودهيلر على قدرتك على قيادة السيارة وتشغيل</p><p>الآلات</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">التزم دائماً بتعليمات طبيبك بكل دقة عند استعمال توبي بودهيلر. راجع الأمر مع</p><p dir="RTL">طبيبك إذا كنت غير متأكد من طريقة الاستعمال.</p><p dir="RTL">يجب على مقدمي الرعاية أن يقدموا العون للأطفال الذين يبدأون في استعمال توبي</p><p dir="RTL">بودهيلر، لاسيما الذين يبلغون من العمر 10 سنوات أو أقل، ويجب أن يستمروا في</p><p dir="RTL">الإشراف عليهم إلى أن يتمكنوا من استعمال بخاخة بودهيلر بشكل صحيح بدون</p><p dir="RTL">مساعدة.</p><p dir="RTL">لا تبلع الكبسولات. يجب أن تؤخذ محتويات كبسولات توبي بودهيلر بالاستنشاق</p><p dir="RTL">فقط باستخدام البخاخة المرفقة بالعبوة. تُستخدم كل بخاخة لمدة سبعة أيام ثم يتم</p><p dir="RTL">التخلص منها واستبدالها. لا ينبغي استعمال أي كبسولات أخرى بواسطة بخاخة</p><p dir="RTL">بودهيلر.</p><p dir="RTL"><strong>ما هي الكمية التي ينبغي أن تأخذها من توبي</strong><strong>&reg;</strong><strong> بودهيلر </strong><strong>&trade;</strong></p><p dir="RTL">يتم استخدام نفس الجرعة في جميع الأشخاص الذين يبلغون من العمر 6 سنوات</p><p dir="RTL">فأكثر: يؤخذ محتوى 4 كبسولات بالاستنشاق مرتين يومياً (صباحاً ومساءً(</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong><strong>متى ينبغي أن تأخذ توبي</strong><strong>&reg;</strong><strong> بودهيلر </strong><strong>&trade;</strong></p><p dir="RTL">إن أخذ توبي بودهيلر في نفس الموعد كل يوم سيساعدك على تذكر موعد استعمال</p><p dir="RTL">دوائك.</p><p dir="RTL">&bull; يؤخذ محتوى 4 كبسوات في الصباح بالاستنشاق باستخدام بخاخة بودهيلر</p><p dir="RTL">&bull; يؤخذ محتوى 4 كبسوات في المساء بالاستنشاق باستخدام بخاخة بودهيلر.</p><p dir="RTL">يجب أن تمر فترة أقرب ما يمكن إلى 12 ساعة بين جرعة الصباح (محتوى 4</p><p dir="RTL">كبسوات بالاستنشاق) وجرعة المساء (محتوى 4 كبسولات بالاستنشاق(</p><p dir="RTL">إذا كنت تستعمل عدة أدوية مختلفة بالاستنشاق وتتلقى علاجات لمرض التليف</p><p dir="RTL">الكيسي، يجب أن تأخذ توبي بودهيلر بعد جميع هذه العلاجات.</p><p dir="RTL">برجاء أن تراجع ترتيب الأدوية مع طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;&nbsp;</strong><strong>ما هي مدة استعمال توبي</strong><strong>&reg;</strong><strong> بودهيلر </strong><strong>&trade;</strong></p><p dir="RTL">بعد أن تأخذ دواءك لمدة 28 يوماً، يجب أن توقف استعمال الدواء لمدة 28 يوماً لا</p><p dir="RTL">تستنشق خلالها أي توبي بودهيلر، قبل أن تبدأ دورة علاجية جديدة.</p><p dir="RTL">من المهم أن تستمر في استعمال المستحضَر مرتين يومياً طوال فترة ال 28 يوماً</p><p dir="RTL">الخاصة بالاستعمال، وأن تلتزم بدورة الاستعمال لمدة 28 يوماً والتوقف لمدة 28</p><p>يوماً</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_2" o:spid="_x0000_s1026" type="#_x0000_t75"
 alt="A black and white text on a white background&#10;&#10;Description automatically generated"
 style='position:absolute;left:0;text-align:left;margin-left:187pt;
 margin-top:14.95pt;width:285.15pt;height:145.95pt;z-index:-251658240;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
 mso-height-relative:margin'>
 <v:imagedata src="file:///C:/Users/nmusa/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title="A black and white text on a white background&#10;&#10;Description automatically generated"/>
 <w:wrap type="tight"/>
</v:shape><![endif]--><img width="570" height="292" alt="A black and white text on a white background

Description automatically generated" src="file:///C:/Users/nmusa/AppData/Local/Temp/msohtmlclip1/01/clip_image002.png" />.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">استمر في استعمال توبي بودهيلر بالطريقة التي يصفها لك طبيبك.</p><p dir="RTL">إذا كانت لديك أسئلة عن مدة استعمال توبي بودهيلر، تحدث مع طبيبك أو مع</p><p dir="RTL">الصيدلي.</p><p dir="RTL"><strong>&nbsp;</strong><strong>كيف تأخذ توبي&reg; بودهيلر &trade;</strong></p><p dir="RTL">انظر البند <strong>7- تعليمات خاصة باستعمال توبي بودهيلر</strong></p><p dir="RTL">التزم بتعليمات طبيبك بكل دقة. لا تتجاوز الجرعة الموصَى بها.</p><p dir="RTL">&nbsp;<strong>ا. إذا أخذت توبي&reg; بودهيلر &trade; بأكثر مما ينبغي</strong></p><p dir="RTL">إذا استنشقت توبي بودهيلر بأكثر مما ينبغي، احرص على إبلاغ طبيبك في أقرب</p><p dir="RTL">وقت ممكن.</p><p dir="RTL">إذا تم بلع كبسولات توبي بودهيلر، أخبر طبيبك في أقرب وقت ممكن.</p><p dir="RTL"><strong>&nbsp;</strong><strong>ب. إذا نسيت أن تأخذ توبي&reg; بودهيلر &trade;</strong></p><p dir="RTL">إذا نسيت أن تأخذ توبي بودهيلر وكانت المدة المتبقية حتى جرعتك التالية 6 ساعات</p><p dir="RTL">على الأقل، خذ جرعتك في أقرب وقت ممكن، وإلا فانتظر حتى جرعتك التالية. لا</p><p dir="RTL">تضاعف الجرعة للتعويض عن الجرعة المنسية.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شأنه شأن جميع الأدوية، فإن المرضى الذين يستعملون توبي بودهيلر قد يتعرضون</p><p dir="RTL">لحدوث آثار جانبية، غير أنها لا تحدث لجميع الأشخاص.</p><p dir="RTL">بعض الآثار الجانبية قد تكون خطيرة</p><p dir="RTL">&bull; صعوبة غير معتادة في التنفس، مع أزيز أو سعال وضيق في الصدر (شائع(</p><p dir="RTL">إذا حدثت لديك أي من هذه الأعراض، توقف عن استعمال توبي بودهيلر <strong>وأخبر</strong></p><p dir="RTL"><strong>طبيبك فوراً</strong>.</p><p dir="RTL">&bull; اشتداد المرض الرئوي الأصلي (شائع جداً(</p><p dir="RTL">&bull; دم في البصاق (شائع جداً(</p><p dir="RTL">&bull; تناقص السمع (إن حدوث طنين في الأذنين قد يكون من العلامات المنذرة</p><p dir="RTL">بفقدان السمع)، ضوضاء (في شكل صفير) في الأذنين (شائع(</p><p dir="RTL">إذا حدث لك أي من هذه الأمور، <strong>أخبر طبيبك فوراً</strong><strong>.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">بعض الآثار الجانبية تكون شائعة جداً</p><p dir="RTL">هذه الآثار الجانبية قد تصيب أكثر من 1 من بين 10 مرضى.</p><p dir="RTL">&bull; ضيق في التنفس</p><p dir="RTL">&bull; سعال، سعال مُنتِج للبلغم، تغير الصوت (بحة في الصوت(</p><p dir="RTL">&bull; التهاب الحلق</p><p dir="RTL">&bull; صداع</p><p dir="RTL">&bull; حمى</p><p dir="RTL">إذا حدثت لك إصابة شديدة بأي من هذه الأمور، <strong>أخبر طبيبك</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بعض الآثار الجانبية تكون شائعة</p><p dir="RTL">هذه الآثار الجانبية قد تصيب بين 1 و 10 من كل 100 مريض</p><p dir="RTL">&bull; أزيز، خرخرة (كراكر(</p><p dir="RTL">&bull; عناء في الصدر، ألم في الصدر نابع من العضات و/أو العظام</p><p dir="RTL">&bull; انقطاع الصوت</p><p dir="RTL">&bull; انخفاض نتائج اختبارات الوظيفة الرئوية</p><p dir="RTL">&bull; ارتفاع مستوى السكر (الجلوكوز) في الدم</p><p dir="RTL">&bull; انسداد الأنف</p><p dir="RTL">&bull; نزف من الأنف</p><p dir="RTL">&bull; قيء، غثيان</p><p dir="RTL">&bull; إسهال</p><p dir="RTL">&bull; طفح</p><p dir="RTL">&bull; خلل في حاسة التذوق.</p><p dir="RTL">إذا حدثت لك إصابة شديدة بأي من هذه الأمور، <strong>أخبر طبيبك</strong><strong>.</strong></p><p dir="RTL">إذا لاحظت أي آثار جانبية أخرى غير مذكورة في هذه النشرة، برجاء أن تخبر</p><p dir="RTL">طبيبك أو الصيدلي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ بعيداً عن متناول ومرأى الأطفال.</p><p dir="RTL">يُحفَظ في درجة حرارة لا تزيد عن س 30&deg;م.</p><p dir="RTL">يُحفَظ في عبوته الأصلية لحمايته من الرطوبة.</p><p dir="RTL">احفظ البخاخة في علبتها المغلقة بإحكام في حالة عدم استعمالها.</p><p dir="RTL">لا تستعمل توبي بودهيلر بعد تاريخ انتهاء الصلاحية المذكور على العبوة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>المادة الفعالة </strong>في توبي بودهيلر هي توبرامايسين</p><p dir="RTL">&bull; <strong>المكونا ت الأخرى </strong>هي:</p><p dir="RTL">المسحوق DSPC (1, 2 دايستيارويل- إ س إ ن- جليسرو- 3- فوسفوكولين),</p><p dir="RTL">كلوريد كالسيوم ، حمض كبريتيك.</p><p dir="RTL">غلاف الكبسولة : هيبروميللوز ، كلوريد بوتاسيوم ، كاراجينان ، شمع الكرنوبا ، حبر</p><p dir="RTL">أزرق.</p><p dir="RTL">هذه المعلوما ت قد تختلف في بعض البلاد.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">توبي بودھیلر ھو مسحوق للاستنشاق (أبیض إلى مائل للأبیض) معبأ داخل</p><p dir="RTL">كبسولا ت صافیة ، عدیمة اللون ، من الھیبرومیللوز ، مطبوع علیھا الحروف &quot;&ldquo; MYL TPH</p><p dir="RTL">بالحبر الأزرق على جزء من الكبسولة ، ومطبوع علیھا شعار</p><p dir="RTL">&nbsp;میلان باللون الأزرق على الجزء الآخر من الكبسولة &nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحتوي كل كبسولة على 28 مجم توبرامايسين.</p><p dir="RTL">يتم استنشاق الكبسولات فقط بواسطة بخاخة بودهيلر المُرفَقة.</p><p dir="RTL">هذه المعلومات قد تختلف في بعض البلاد.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ج. صاحب حق التسويق</strong></p><p dir="RTL">صاحب حق الامتياز التجاري:</p><p dir="RTL">ميلان فارما ش. ذ. م. م &nbsp;</p><p dir="RTL">، ترمستراس 24</p><p dir="RTL">6312 شتاينهاوسن ، سويسرا</p><p dir="RTL">هاتف: 48 41+ (0) 41 768 48</p><p dir="RTL">فاكس: 49 41+ (0) 41 768 48</p><p dir="RTL">بريد إلكتروني info.ch@mylan.com :</p><p dir="RTL">&nbsp;</p><p dir="RTL">الشركة المصنعة:</p><p dir="RTL">ميلان فارماسيوتيكالز إنك.</p><p dir="RTL">150 الطريق الصناعي، سان كارلوس،</p><p dir="RTL">كاليفورنيا 94070 ، الولايات المتحدة الأمريكية</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم تنقیح ھذه النشرة في فبرایر 2024
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                TOBI Podhaler 28 mg inhalation powder, hard capsules
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each hard capsule contains 28 mg tobramycin. For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Inhalation powder, hard capsule

Clear colourless capsules containing a white to almost white powder, with “MYL TPH” printed in blue
on one part of the capsule and Mylan logo printed in blue on the other part of the capsule




            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>TOBI Podhaler is indicated for the suppressive therapy of chronic pulmonary infection due to</p><p>Pseudomonas aeruginosa in adults and children aged 6 years and older with cystic fibrosis. See sections 4.4 and 5.1 regarding data in different age groups.</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>The dose of TOBI Podhaler is the same for all patients within the approved age range, regardless of age or weight. The recommended dose is 112 mg tobramycin (4 x 28 mg capsules), administered twice daily for 28 days. TOBI Podhaler is taken in alternating cycles of 28 days on treatment followed by 28 days off treatment. The two doses (of 4 capsules each) should be inhaled as close as possible to 12 hours apart and not less than 6 hours apart.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Missed doses</u></p><p>In case of missed dose with at least 6 hours until the next dose, the patient should take the dose as soon as possible. Otherwise, the patient should wait for the next dose and not inhale more capsules to make up for the missed dose.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Duration of treatment</u></p><p>Treatment with TOBI Podhaler should be continued on a cyclical basis for as long as the physician considers the patient is gaining clinical benefit from the treatment with TOBI Podhaler. If clinical deterioration of pulmonary status is evident, additional or alternative anti-pseudomonal therapy should be considered. See also information on clinical benefit and tolerability in sections 4.4, 4.8 and 5.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Special populations</u></p><p><em><u>Elderly patients</u></em><em> (&ge;65 </em>years)</p><p>There are insufficient data in this population to support a recommendation for or against dose adjustment.</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>Tobramycin is primarily excreted unchanged in the urine and renal function is expected to affect the exposure to tobramycin. Patients with serum creatinine 2 mg/dl or more and blood urea nitrogen (BUN) 40 mg/dl or more have not been included in clinical studies and there are no data in this population to support a recommendation for or against dose adjustment with TOBI Podhaler. Caution should be exercised when prescribing TOBI Podhaler to patients with known or suspected renal dysfunction.</p><p>&nbsp;</p><p>Please also refer to nephrotoxicity information in section 4.4.</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p>No studies have been performed on patients with hepatic impairment. As tobramycin is not metabolised, an effect of hepatic impairment on the exposure to tobramycin is not expected.</p><p>&nbsp;</p><p><u>Patients after organ transplantation</u></p><p>Adequate data do not exist for the use of TOBI Podhaler in patients after organ transplantation. No recommendation for or against dose adjustment can be made for patients after organ transplantation.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The safety and efficacy of TOBI Podhaler in children aged under 6 years have not been established. No data are available.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inhalation use.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; TOBI Podhaler is administered by inhalation using the Podhaler device (see section 6.6 for detailed instructions&nbsp;&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for use). It must not be administered by any other route or using any other inhaler.</p><p>&nbsp;</p><p>Caregivers should provide assistance to children starting TOBI Podhaler treatment, particularly those aged 10 years or younger, and should continue to supervise them until they are able to use the Podhaler device properly without help.</p><p>&nbsp;</p><p>TOBI Podhaler capsules must not be swallowed. Each TOBI Podhaler capsule should be inhaled with two breath-hold manoeuvres and checked to ensure it is empty.</p><p>&nbsp;</p><p>Where patients are receiving several different inhaled medicinal products and chest physiotherapy, it is recommended that TOBI Podhaler is taken last.</p><p>&nbsp;</p><p>&nbsp;&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance and any aminoglycoside, or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Ototoxicity</u></p><p>Ototoxicity, manifested as both auditory toxicity (hearing loss) and vestibular toxicity, has been reported with parenteral aminoglycosides. Vestibular toxicity may be manifested by vertigo, ataxia or dizziness. Tinnitus may be a sentinel symptom of ototoxicity, and therefore the onset of this symptom warrants caution.</p><p>&nbsp;</p><p>Hearing loss and tinnitus were reported by patients in the TOBI Podhaler clinical studies (see section 4.8). Caution should be exercised when prescribing TOBI Podhaler to patients with known or suspected auditory or vestibular dysfunction.</p><p>&nbsp;</p><p>In patients with any evidence of auditory dysfunction, or those with a predisposing risk, it may be necessary to consider audiological assessment before initiating TOBI Podhaler therapy.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Risk of Ototoxicity Due to Mitochondrial DNA Variants</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cases of ototoxicity with aminoglycosides have been observed in patients with certain variants in the&nbsp;&nbsp; &nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mitochondrially encoded 12S rRNA gene (MT-RNR1), particularly the m.1555A&gt;G variant. Ototoxicity</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; occurred in some patients even when their aminoglycoside serum levels were within the recommended range.&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mitochondrial DNA variants are present in less than 1% of the general US population, and the proportion of the</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; variant carriers who may develop ototoxicity as well as the severity of ototoxicity is unknown. In case of</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; known maternal history of ototoxicity due to aminoglycoside use or a known mitochondrial DNA variant in the</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; patient, consider alternative treatments other than aminoglycosides unless the increased risk of permanent&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hearing loss is outweighed by the severity of infection and lack of safe and effective alternative therapies.</p><p>&nbsp;</p><p>If a patient reports tinnitus or hearing loss during TOBI Podhaler therapy the physician should consider referring them for audiological assessment.</p><p>&nbsp;</p><p>See also &ldquo;Monitoring of serum tobramycin concentrations&rdquo; below.</p><p>&nbsp;</p><p><u>Nephrotoxicity</u></p><p>Nephrotoxicity has been reported with the use of parenteral aminoglycosides. Nephrotoxicity was not observed during TOBI Podhaler clinical studies. Caution should be exercised when prescribing TOBI Podhaler to patients with known or suspected renal dysfunction. Baseline renal function should be assessed. Urea and creatinine levels should be reassessed after every 6 complete cycles of TOBI Podhaler therapy.</p><p>&nbsp;</p><p>See also section 4.2 and &ldquo;Monitoring of serum tobramycin concentrations&rdquo; below.</p><p>&nbsp;</p><p><u>Monitoring of serum tobramycin concentrations</u></p><p>Patients with known or suspected auditory or renal dysfunction should be monitored for serum tobramycin concentrations. If oto- or nephrotoxicity occurs in a patient receiving TOBI Podhaler, tobramycin therapy should be discontinued until serum concentration falls below 2 &micro;g/ml.</p><p>&nbsp;</p><p>Serum concentrations greater than 12 &micro; g/ml are associated with tobramycin toxicity and treatment should be discontinued if concentrations exceed this level.</p><p>&nbsp;</p><p>The serum concentration of tobramycin should only be monitored through validated methods. Finger prick blood sampling is not recommended due to the risk of contamination of the sample.</p><p>&nbsp;</p><p><u>Bronchospasm</u></p><p>Bronchospasm can occur with inhalation of medicinal products and has been reported with TOBI Podhaler in clinical studies. Bronchospasm should be treated as medically appropriate.</p><p>&nbsp;</p><p>The first dose of TOBI Podhaler should be given under supervision, after using a bronchodilator if this is part of the current regimen for the patient. FEV<sub>1</sub> should be measured before and after inhalation of TOBI Podhaler.</p><p>&nbsp;</p><p>&nbsp;<p>&nbsp;</p></p><p>If there is evidence of therapy-induced bronchospasm, the physician should carefully evaluate whether the benefits of continued use of TOBI Podhaler outweigh the risks to the patient. If an allergic response is suspected, TOBI Podhaler should be discontinued.</p><p>&nbsp;</p><p><u>Cough</u></p><p>Cough can occur with the use of inhaled medicinal products and was reported with use of TOBI Podhaler in clinical studies. Based on clinical trial data the inhalation powder TOBI Podhaler was associated with a higher reported rate of cough compared with tobramycin nebuliser solution (TOBI). Cough was not related to bronchospasm. Children below the age of 13 years may be more likely to cough when treated with TOBI Podhaler compared with older subjects.</p><p>&nbsp;</p><p>If there is evidence of continued therapy-induced cough with TOBI Podhaler, the physician should consider whether an approved tobramycin nebuliser solution should be used as an alternative treatment. Should cough remain unchanged, other antibiotics should be considered.</p><p>&nbsp;</p><p><u>Haemoptysis</u></p><p>Haemoptysis is a complication in cystic fibrosis and is more frequent in adults. Patients with haemoptysis (&gt;60 ml) were excluded from the clinical studies so no data exist on the use of TOBI Podhaler in these patients. This should be taken into account before prescribing TOBI Podhaler, considering the inhalation powder TOBI Podhaler was associated with a higher rate of cough (see above). The use of TOBI Podhaler in patients with clinically significant haemoptysis should be undertaken or continued only if the benefits of treatment are considered to outweigh the risks of inducing further haemorrhage.</p><p>&nbsp;</p><p><u>Other precautions</u></p><p>Patients receiving concomitant parenteral aminoglycoside therapy (or any medication affecting renal excretion, such as diuretics) should be monitored as clinically appropriate taking into account the risk of cumulative toxicity. This includes monitoring of serum concentrations of tobramycin. In patients with a predisposing risk due to previous prolonged, systemic aminoglycoside therapy it may be necessary to consider renal and audiological assessment before initiating TOBI Podhaler therapy.</p><p>&nbsp;</p><p>See also &ldquo;Monitoring of serum tobramycin concentrations&rdquo; above.</p><p>&nbsp;</p><p>Caution should be exercised when prescribing TOBI Podhaler to patients with known or suspected neuromuscular disorders such as myasthenia gravis or Parkinson&rsquo;s disease. Aminoglycosides may aggravate muscle weakness because of a potential curare-like effect on neuromuscular function.</p><p>&nbsp;</p><p>The development of antibiotic-resistant P. aeruginosa and superinfection with other pathogens represent potential risks associated with antibiotic therapy. In clinical studies, some patients on TOBI Podhaler therapy showed an increase in aminoglycoside minimum inhibitory concentrations (MIC) for P.</p><p>aeruginosa isolates tested. MIC increases observed were in large part reversible during off-treatment periods.</p><p>&nbsp;</p><p>There is a theoretical risk that patients being treated with TOBI Podhaler may develop P. aeruginosa isolates resistant to intravenous tobramycin over time (see section 5.1). Development of resistance during inhaled tobramycin therapy could limit treatment options during acute exacerbations; this should be monitored.</p><p>&nbsp;<p>&nbsp;</p></p><p><u>Data in different age groups</u></p><p>In a 6-month (3 treatment cycles) study of TOBI Podhaler versus tobramycin nebuliser solution (TOBI), which included a majority of tobramycin-experienced adult patients with chronic pulmonary P.</p><p>aeruginosa infection, the suppression of sputum P. aeruginosa density was similar across age groups in both arms; however the increase from baseline FEV<sub>1</sub> was larger in younger age groups (6 - &lt;20) than in the adult subgroup (20 years and older) in both arms. See also section 5.1 for the profile of response of TOBI Podhaler compared to tobramycin nebuliser solution. Adult patients tended to discontinue more frequently for tolerability reasons with TOBI Podhaler than with the nebuliser solution. See also section 4.8.</p><p>&nbsp;</p><p>If clinical deterioration of pulmonary status is evident, additional or alternative anti-pseudomonal therapy should be considered.</p><p>&nbsp;</p><p>Observed benefits on lung function and P. aeruginosa suppression should be assessed in the context of</p><p>the patient&rsquo;s tolerance of TOBI Podhaler.</p><p>&nbsp;</p><p>Safety and efficacy have not been studied in patients with forced expiratory volume in 1 second (FEV<sub>1</sub>)</p><p>&lt;25% or &gt;80% predicted, or patients colonised with Burkholderia cepacia.</p><table cellspacing="0" cellpadding="0" align="left"><tbody></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interaction studies have been performed with TOBI Podhaler. Based on the interaction profile for tobramycin following intravenous and aerosolised administration, concurrent and/or sequential use of</p><p>TOBI Podhaler is not recommended with other medicinal products with nephrotoxic or ototoxic potential.</p><p>&nbsp;</p><p>Concomitant use of TOBI&nbsp; Podhaler&nbsp; with diuretic compounds&nbsp; (such as ethacrynic acid, furosemide, urea or intravenous mannitol) is not recommended. Such coumpounds can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue.</p><p>&nbsp;</p><p>See also information on previous and concomitant use of systemic aminoglycosides and diuretics in section 4.4.</p><p>&nbsp;</p><p>Other medicinal products that have been reported to increase the potential toxicity of parenterally administered aminoglycosides include:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; amphotericin B, cefalotin, ciclosporin, tacrolimus, polymyxins (risk of increased nephrotoxicity);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; platinum compounds (risk of increased nephrotoxicity and ototoxicity);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anticholinesterases, botulinum toxin (neuromuscular effects).</p><p>&nbsp;</p><p>In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids and macrolides, no evidence of drug interactions with these medicines was identified.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are no adequate data on the use of tobramycin via inhalation in pregnant women. Animal studies with tobramycin do not indicate a teratogenic effect (see section 5.3). However, aminoglycosides can cause foetal harm (e.g. congenital deafness) when high systemic concentrations are achieved in a</p><p>pregnant woman. Systemic exposure following inhalation of TOBI Podhaler is very low, however TOBI Podhaler should not be used during pregnancy unless clearly necessary, i.e. when the benefits to the mother outweigh the risks to the foetus. Patients who use TOBI Podhaler during pregnancy, or become pregnant while taking TOBI Podhaler, should be informed of the potential hazard to the foetus.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>Tobramycin is excreted in human breast milk after systemic administration. The amount of tobramycin excreted in human breast milk after administration by inhalation is not known, though it is estimated to be very low considering the low systemic exposure. Because of the potential for ototoxicity and</p><p>nephrotoxicity in infants, a decision should be made whether to terminate breast-feeding or discontinue treatment with TOBI Podhaler, taking into account the importance of the treatment to the mother.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>No effect on male or female fertility was observed in animal studies after subcutaneous administration (see section 5.3).</p><p>&nbsp;</p><p>&nbsp;</p><table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>On the basis of the pharmacodynamic profile and reported adverse drug reactions, TOBI Podhaler is not expected to adversely affect the ability to drive and use machines. No specific studies on the effects on the ability to drive and use machines have been performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p><u>Summary of safety profile</u></p><p>&nbsp;</p><p>The most commonly reported adverse reactions in the main safety, active-controlled clinical study with TOBI Podhaler versus tobramycin nebuliser solution in cystic fibrosis patients with P. aeruginosa infection were cough, productive cough, pyrexia, dyspnoea, oropharyngeal pain, dysphonia and haemoptysis.</p><p>&nbsp;</p><p>In the placebo-controlled study with TOBI Podhaler, the adverse reactions for which reported frequency was higher with TOBI Podhaler than with placebo were pharyngolaryngeal pain, dysgeusia and dysphonia.</p><p>The vast majority of adverse reactions reported with TOBI Podhaler were mild or moderate, and severity did not appear to differ between cycles or between the entire study and on-treatment periods.</p><p>&nbsp;</p><p><u>Tabulated summary of adverse reactions</u></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse drug reactions in Table&nbsp;1 are listed according to system organ classes in MedDRA. Within each system&nbsp;&nbsp;&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; organ class, the adverse drug reactions are ranked by frequency, with the most frequent reactions first. Within each&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; frequency grouping, adverse drug reactions are presented in order of decreasing seriousness. In addition, the&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; corresponding frequency category for each adverse drug reaction is based on the following convention (CIOMS III):</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000);&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;very rare (&lt;1/10,000); not known: frequency cannot be estimated from the available data.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The frequencies in Table&nbsp;1 are based on the reporting rates from the active-controlled study.</p><p><strong>Table 1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse reactions</strong></p><p><!--[if gte vml 1]><o:wrapblock><v:group
  id="Group_x0020_6" o:spid="_x0000_s1030" style='position:absolute;
  margin-left:57.25pt;margin-top:16.25pt;width:461.25pt;height:.5pt;z-index:-251657216;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' coordorigin="1145,325" coordsize="9225,10"
  o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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=
">
  <v:line id="Line_x0020_9" o:spid="_x0000_s1031" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="1145,330" to="7960,330"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" strokeweight=".48pt"/>
  <v:rect id="Rectangle_x0020_8" o:spid="_x0000_s1032" style='position:absolute;
   left:7959;top:324;width:10;height:10;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" fillcolor="black" stroked="f"/>
  <v:line id="Line_x0020_7" o:spid="_x0000_s1033" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="7969,330" to="10370,330"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" strokeweight=".48pt"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:group><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="924" height="2" src="file:///C:/Users/nmusa/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></td></tr></tbody></table><!--[if gte vml 1]></o:wrapblock><![endif]--><p>&nbsp;</p><p><strong>Adverse reactions&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Frequency category</strong></p><p><!--[if gte vml 1]><o:wrapblock><v:group
  id="Group_x0020_2" o:spid="_x0000_s1026" style='position:absolute;
  margin-left:57.25pt;margin-top:9.25pt;width:461.25pt;height:.5pt;z-index:-251656192;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' coordorigin="1145,185" coordsize="9225,10"
  o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
  <v:line id="Line_x0020_5" o:spid="_x0000_s1027" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="1145,190" to="7960,190"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" strokeweight=".48pt"/>
  <v:rect id="Rectangle_x0020_4" o:spid="_x0000_s1028" style='position:absolute;
   left:7959;top:185;width:10;height:10;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" fillcolor="black" stroked="f"/>
  <v:line id="Line_x0020_3" o:spid="_x0000_s1029" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="7969,190" to="10370,190"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight=".48pt"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:group><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="924" height="2" src="file:///C:/Users/nmusa/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></td></tr></tbody></table><!--[if gte vml 1]></o:wrapblock><![endif]--><p>&nbsp;</p><p><strong>Ear and labyrinth disorders</strong></p><p>Hearing loss&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common</p><p>Tinnitus&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common</p><p><strong>Vascular disorders</strong></p><p>Haemoptysis&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Very common</p><p>Epistaxis&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common</p><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p><p>Dyspnoea&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Very common</p><p>Dysphonia&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Very common</p><p>Productive cough&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Very common</p><p>Cough&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Very common</p><p>Wheezing&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common</p><p>Rales&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common</p><p>Chest discomfort&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common</p><p>Nasal congestion&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common</p><p>Bronchospasm&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common</p><p>Aphonia&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common</p><p>Sputum discoloured&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Not known</p><p><strong>Gastrointestinal disorders</strong></p><p>Oropharnygeal pain&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Very common</p><p>Vomiting&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common</p><p>Diarrhoea&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common</p><p>Throat irritation&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common</p><p>Nausea&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common</p><p>Dysgeusia&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common</p><p><strong>Skin and subcutaneous tissue disorders</strong></p><p>Rash&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common</p><p><strong>Musculoskeletal, connective tissue and bone disorders</strong></p><p>Musculoskeletal chest pain&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common</p><p><strong>General disorders and administration site conditions</strong></p><p>Pyrexia&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Very common</p><p>Malaise&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Not known&nbsp;</p><p>&nbsp;&nbsp;</p>&nbsp;<p>&nbsp;</p><p><u>Description of selected adverse drug reactions</u></p><p>Cough was the most frequently reported adverse reaction in both clinical studies. However, no</p><p>association was observed in either clinical study between the incidence of bronchospasm and cough events.</p><p>&nbsp;</p><p>In the active-controlled study, audiology testing was performed in selected centres accounting for about a quarter of the study population. Four patients in the TOBI Podhaler treatment group experienced significant decreases in hearing which were transient in three patients and persistent in one case.</p><p>&nbsp;</p><p>In the active-controlled open-label study, patients aged 20 years and older tended to discontinue more frequently with TOBI Podhaler than with the nebuliser solution (TOBI); discontinuations due to adverse</p><p>events accounted for about half of the discontinuations with each formulation. In children under 13 years of age, discontinuations were more frequent in the TOBI nebuliser solution arm whereas in patients aged 13 to 19, discontinuation rates with both formulations were similar.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions</p><p>&nbsp;</p><p>&nbsp;</p><p>--To reports any side effect(s):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><p>The National Pharmacovigilance Centre (NPC) Fax: +966-11-205-7662</p><p>SFDA Call Center: 19999</p><p>E-mail:npc.drug@sfda.gov.sa Website: https://ade.sfda.gov.sa/</p><p>&nbsp;</p><p><strong><em>Other GCC States:</em></strong></p><p>Please contact the relevant competent authority.</p>&nbsp;<p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p>Adverse reactions specifically associated with overdose of TOBI Podhaler have not been identified. The maximum tolerated daily dose of TOBI Podhaler has not been established. Tobramycin serum concentrations may be helpful in monitoring overdosage. In case of signs of acute toxicity, immediate withdrawal of TOBI Podhaler and testing of renal function are recommended. In the event of accidental oral ingestion of TOBI Podhaler capsules, toxicity is unlikely as tobramycin is poorly absorbed from an intact gastrointestinal tract. Haemodialysis may be helpful in removing tobramycin from the body.</p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antibacterials for systemic use, Aminoglycoside antibacterials, ATC Code: J01GB01</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Tobramycin is an aminoglycoside antibiotic produced by Streptomyces tenebrarius. It acts primarily by disrupting protein synthesis leading to altered cell membrane permeability, progressive disruption of the cell envelope and eventual cell death. It is bactericidal at concentrations equal to or slightly greater than inhibitory concentrations.</p><p>&nbsp;</p><p><u>Breakpoints</u></p><p>Established susceptibility breakpoints for parenteral administration of tobramycin are inappropriate in the aerosolised administration of the medicinal product.</p><p>&nbsp;</p><p>Sputum from cystic fibrosis exhibits an inhibitory action on the local biological activity of inhaled</p><p>aminoglycosides. This necessitates sputum concentrations of tobramycin after inhalation to be about ten- fold above the minimum inhibitory concentration (MIC) or higher for P. aeruginosa suppression. In the active-controlled study, at least 89% of patients had P. aeruginosa isolates with MICs at least 15 times lower than mean post-dose sputum concentration, both at baseline and at the end of the third active</p><p>treatment cycle.</p><p>&nbsp;</p><p><u>Susceptibility</u></p><p>In the absence of conventional susceptibility breakpoints for the inhaled route of administration, caution must be exercised in defining organisms as susceptible or insusceptible to inhaled tobramycin.</p><p>&nbsp;</p><p>The clinical significance of changes in MICs of tobramycin for P. aeruginosa has not been clearly</p><p>established in the treatment of cystic fibrosis patients. Clinical studies with inhaled tobramycin solution (TOBI) have shown a small increase in tobramycin, amikacin and gentamicin Minimum Inhibitory Concentrations for P. aeruginosa isolates tested. In the open label extensions, each additional 6 months of treatment resulted in incremental increases similar in magnitude to that observed in the 6 months of placebo-controlled studies.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Resistance to tobramycin involves different mechanisms. The main resistance mechanisms are drug efflux and drug inactivation by modifying enzymes. The unique characteristics of chronic P. aeruginosa infections in CF patients, such as anaerobic conditions and high frequency of genetic mutations, may also be important factors for reduced susceptibility of P. aeruginosa in CF patients.</p><p>&nbsp;</p><p>Based upon in vitro data and/or clinical trial experience, the organisms associated with pulmonary infections in CF may be expected to respond to TOBI Podhaler therapy as follows:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Susceptible</p></td><td style="vertical-align:top"><p>Pseudomonas aeruginosa Haemophilus influenzae Staphylococcus aureus</p></td></tr><tr><td style="vertical-align:top"><p>Insusceptible</p></td><td style="vertical-align:top"><p>Burkholderia cepacia</p><p>Stenotrophomonas maltophilia Alcaligenes xylosoxidans</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Clinical experience</u></p><p>The TOBI Podhaler Phase III clinical development programme consisted of two studies and 612 treated patients with a clinical diagnosis of CF, confirmed by quantitative pilocarpine iontophoresis sweat chloride test or well-characterised disease causing mutations in each cystic fibrosis transmembrane</p><p>regulator&nbsp; (CFTR) gene, or&nbsp; abnormal nasal transepithelial potential difference characteristic of CF.</p><p>&nbsp;</p><p>In the placebo controlled study, patients were aged 6 - <em>&le;22 </em>years with an FEV<sub>1</sub> at screening of between 25% and 84% of predicted normal values for their age, sex and height based upon Knudson criteria. In the active controlled studies, all patients were aged &gt; 6years old (range 6-66 years) with an FEV<sub>1</sub> %</p><p>predicted at screening of between 24% and 76%. In addition, all patients were infected with P.</p><p>aeruginosa as demonstrated by a positive sputum or&nbsp; throat culture (or&nbsp; bronchoalveolar lavage) within 6 months prior to screening, and also in a sputum culture taken at the screening visit.</p><p>&nbsp;</p><p>In a randomised, double-blind, placebo-controlled, multicentre study, TOBI Podhaler 112 mg (4 x 28 mg capsules) was administered twice daily, for three cycles of 28 days on-treatment and 28 days off-</p><p>treatment (a total treatment period of 24 weeks). Patients who were randomised to the placebo treatment group received placebo during the first treatment cycle and TOBI Podhaler in the subsequent two cycles. Patients in this study had no exposure to inhaled tobramycin for at least 4 months prior to study start.</p><p>&nbsp;</p><p>TOBI Podhaler significantly improved lung function compared with placebo, as shown by the relative increase in percent predicted FEV<sub>1</sub> of about 13% after 28 days of treatment. The improvements in lung function achieved during the first treatment cycle were maintained during the two subsequent cycles of treatment with TOBI Podhaler.</p><p>&nbsp;</p><p>When patients in the placebo treatment group were switched from placebo to TOBI Podhaler&nbsp; at the start of the second treatment cycle, they experienced a similar improvement from baseline in percent predicted FEV<sub>1</sub>. Treatment with TOBI Podhaler for 28 days resulted in a statistically significant reduction in P.</p><p>&nbsp;</p><p>&nbsp;</p><p>aeruginosa sputum density (mean difference with placebo about 2.70 log<sub>10</sub> in colony forming units/CFUs).</p><p>&nbsp;</p><p>In a second open-label, multicentre study, patients received treatment with either TOBI Podhaler</p><p>(112 mg) or tobramycin 300 mg/5 ml nebuliser solution (TOBI), administered twice daily for&nbsp; three cycles. A majority of the patients were tobramycin-experienced adults with chronic pulmonary P. aeruginosa infection.</p><p>&nbsp;</p><p>Treatment with both TOBI Podhaler and tobramycin 300 mg/5 ml nebuliser solution (TOBI) resulted in relative increases from baseline to day 28 of the third treatment cycle in percent predicted FEV<sub>1</sub> of 5.8%</p><p>and 4.7%, respectively. The improvement in percent predicted FEV<sub>1</sub> was numerically greater in the TOBI Podhaler treatment group and was statistically non-inferior to TOBI nebuliser solution. Although the</p><p>magnitude of improvements in lung function was smaller in this study, this is explained by the previous exposure of this patient population to treatment with inhaled tobramycin. Over half of the patients in both the TOBI Podhaler and TOBI nebuliser solution treatment groups received new (additional) anti- pseudomonal antibiotics (64.9% and 54.5% respectively, the difference consisting mainly of oral</p><p>ciprofloxacin use). The proportions of patients requiring hospitalisation for respiratory events were 24.4% with TOBI Podhaler and 22.0% with TOBI nebuliser solution.</p><p>&nbsp;</p><p>A difference in FEV<sub>1</sub> response by age was noted. In the patients aged &lt; 20 years the increase from baseline percent predicted FEV<sub>1</sub> was larger: 11.3% for TOBI Podhaler and 6.9% for the nebuliser solution after 3 cycles. <em>A numerically lower response in patients aged &ge;20 </em>years was observed: the change from baseline FEV<sub>1</sub> <em>observed in the patients aged &ge;20 </em>years was smaller (0.3% with TOBI Podhaler and 0.9% with TOBI nebuliser solution).</p><p>&nbsp;</p><p>Furthermore, an improvement of 6% in percent predicted FEV<sub>1</sub> was obtained in about 30% versus 36% of the adult patients in the TOBI Podhaler and TOBI nebuliser solution group respectively.</p><p>&nbsp;</p><p>Treatment with TOBI Podhaler for 28 days resulted in a statistically significant reduction in P. aeruginosa sputum density (-1.61 log<sub>10</sub> CFUs), as did the nebuliser solution (-0.77 log<sub>10</sub> CFUs).</p><p>Suppression of sputum P. aeruginosa density was similar across age groups in both arms. In both studies, there was a trend for a recovery of P. aeruginosa density after the 28 days off-treatment period, which</p><p>was reversed after a further 28 days on-treatment.</p><p>&nbsp;</p><p>In the active-controlled study, administration of a TOBI Podhaler dose was faster with a&nbsp; mean difference of approximately 14 minutes (6 minutes vs. 20 minutes with the nebuliser solution). Patient-reported convenience and overall treatment satisfaction (as collected through a patient-reported outcomes questionnaire) were consistently higher&nbsp; with TOBI Podhaler&nbsp; compared with tobramycin nebuliser solution in each cycle.</p><p>&nbsp;</p><p>For safety results see section 4.8.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><u>Absorption</u></p><p>The systemic exposure to tobramycin after inhalation of TOBI Podhaler is expected to be primarily from the inhaled portion of the medicinal product as tobramycin is not absorbed to any appreciable extent when administered via the oral route.</p><p>&nbsp;</p><p><u>Serum concentrations: </u></p><p>After inhalation of a 112 mg single dose (4 x 28 mg capsules) of TOBI Podhaler in cystic fibrosis patients, the maximum serum concentration (C<sub>max</sub>) of tobramycin was 1.02 &plusmn; 0.53 <em>&mu;g/ml </em>(mean &plusmn; SD) and the median time to reach the peak concentration (T<sub>max</sub>) was one hour. In comparison,</p><p>after inhalation of a single dose of tobramycin 300 mg/5 ml nebuliser solution (TOBI), C<sub>max</sub> was</p><p>1.04 &plusmn; 0.58 &micro; g/ml and median T<sub>max</sub> was one hour. The extent of systemic exposure (AUC) was also similar for the 112 mg TOBI Podhaler dose and the 300 mg tobramycin nebuliser solution dose. At the end of a</p><p>4-week dosing cycle of TOBI Podhaler (112 mg twice daily), maximum serum concentration of tobramycin 1 hour after dosing was 1.99 &plusmn; 0.59 &micro; g/ml.</p><p>&nbsp;</p><p><u>Sputum concentrations: </u></p><p>After&nbsp; inhalation of a&nbsp; 112 mg single dose (4 x 28 mg capsules) of TOBI Podhaler in cystic fibrosis patients, sputum C<sub>max</sub> of tobramycin was 1047 &plusmn; 1080 &micro; g/g (mean &plusmn; SD). In comparison, after inhalation of a single 300 mg dose of tobramycin nebuliser solution (TOBI), sputum C<sub>max</sub> was</p><p>737.3 &plusmn; 1028.4 &micro; g/g. The variability in pharmacokinetic parameters was higher in sputum as compared to serum.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>A population pharmacokinetic analysis for TOBI Podhaler in cystic fibrosis patients estimated the</p><p>apparent volume of distribution of tobramycin in the central compartment to be 84.1 litres for a typical CF patient. While the volume was shown to vary with body mass index (BMI) and lung function (as</p><p>FEV<sub>1</sub>% predicted), model-based simulations showed that peak (C<sub>max</sub>) and trough (C<sub>trough</sub>) concentrations were not impacted markedly with changes in BMI or lung function.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Tobramycin is not metabolised and is primarily excreted unchanged in the urine.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>Tobramycin is eliminated from the systemic circulation primarily by glomerular filtration of the unchanged compound. The apparent terminal half-life of tobramycin in serum after inhalation of a 112 mg single dose of TOBI Podhaler was approximately 3 hours in cystic fibrosis patients and consistent with the half-life of tobramycin after inhalation of tobramycin 300 mg/5 ml nebuliser solution (TOBI).</p><p>&nbsp;</p><p>A population pharmacokinetic analysis for TOBI Podhaler in cystic fibrosis patients aged 6 to 66 years estimated the apparent serum clearance of tobramycin to be 14 litres/h. This analysis did not show gender or age-related pharmacokinetic differences</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal that the main hazard for humans, based on studies of safety pharmacology, repeated dose toxicity, genotoxicity, or toxicity to reproduction, consists of renal toxicity and ototoxicity. In general, toxicity is seen at higher systemic tobramycin levels than are achievable by inhalation at the recommended clinical dose.</p><p>&nbsp;</p><p>Carcinogenicity studies with inhaled tobramycin do not increase the incidence of any variety of tumour. Tobramycin showed no genotoxic potential in a battery of genotoxicity tests.</p><p>&nbsp;</p><p>No reproduction toxicology studies have been conducted with tobramycin administered by inhalation. However, subcutaneous administration of tobramycin during organogenesis was not teratogenic nor embryotoxic. Severely maternally toxic doses to female rabbits (i.e. nephrotoxicity) lead to spontaneous abortions and death. Based on available data from animals a risk of toxicity (e.g. ototoxicity) at prenatal exposure levels cannot be excluded.</p><p>&nbsp;</p><p>Subcutaneous administration of tobramycin did not affect mating behaviour or cause impairment of fertility in male or female rats.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Capsule content</u></p><p>1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) Calcium chloride</p><p>Sulfuric acid (for pH adjustment)</p><p>&nbsp;</p><table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p>Not applicable</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4 years
Discard the Podhaler device and its case 1 week after first use.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>TOBI Podhaler capsules must always be stored in the blister to protect from moisture and only removed immediately before use.</p><p>Don&rsquo;t store above 30⁰C.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The hard capsules are supplied in PVC/PA/Alu/PVC- PET/Alu blisters.</p><p>The Podhaler inhalation device and its storage case are made from plastic materials (polypropylene).</p><p>&nbsp;</p><p>TOBI Podhaler is supplied in monthly packs containing 4 weekly cartons and a reserve Podhaler device in its storage case. Each weekly carton contains 56 x 28 mg capsules (7 blister strips with 8 capsules per strip), and a Podhaler device in its storage case.</p><p>Pack sizes:</p><p>56 capsules and 1 inhaler</p><p>224 (4 x 56) capsules and 5 inhalers (monthly multipack)</p><table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Only TOBI Podhaler capsules are to be used in the Podhaler device. No other inhaler may be used. TOBI Podhaler capsules must always be stored in the blister strip (capsule card), and only removed immediately before use. Each Podhaler device and its case are used for seven days and then discarded and replaced. Store the Podhaler device in its tightly closed case when not in use.</p><p>&nbsp;</p><p>Basic instructions for use are given below, more detailed instructions are available from the patient leaflet.</p><p>&nbsp;</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wash and fully dry hands.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Just before use, remove the Podhaler device from its case. Briefly inspect the inhaler to make sure it is not damaged or dirty.</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Holding the body of the inhaler, unscrew and remove the mouthpiece from the inhaler body. Set the mouthpiece aside on a clean, dry surface.</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Separate the morning and evening doses from the capsule card.</p><p>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Peel back the foil from the capsule card to reveal one TOBI Podhaler capsule and remove it from the card.</p><p>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Immediately insert the capsule into the inhaler chamber. Replace the mouthpiece and screw it on firmly until it stops. Do not overtighten.</p><p>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To puncture capsule, hold the inhaler with the mouthpiece down, press the button firmly with your thumb as far as it will go, then release the button.</p><p>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fully exhale away from the inhaler.</p><p>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Place mouth over the mouthpiece creating a tight seal. Inhale the powder deeply with a single continuous inhalation.</p><p>10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove inhaler from mouth, and hold breath for approximately 5 seconds, then exhale normally away from the inhaler.</p><p>11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After a few normal breaths away from the inhaler, perform a second inhalation from the same capsule.</p><p>12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Unscrew mouthpiece and remove the capsule from the chamber.</p><p>13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inspect the used capsule. It should appear punctured and empty.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If the capsule is punctured but still contains some powder, place it back into the inhaler and take another two inhalations from the capsule. Reinspect capsule.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If the capsule appears to be unpunctured, place it back into the inhaler, press the button firmly as far as it goes and take another two inhalations from the capsule. After this if the capsule is still full and appears to be unpunctured, replace the inhaler with the reserve inhaler and try again.</p><p>14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Discard the empty capsule.</p><p>15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Repeat, starting at step 5, for the remaining three capsules of the dose.</p><p>16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Replace the mouthpiece and screw it on firmly until it stops. When the full dose (4 capsules) has been inhaled, wipe mouthpiece with a clean dry cloth.</p><p>17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Place inhaler back in storage case and close tightly. The inhaler should never be washed with water.</p><p>&nbsp;</p><p>See also section 4.2.</p><p>&nbsp;</p><p>Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Mylan Pharma  GmbH Turmstrasse 24, 6312 Steinhausen, Switzerland




8. Marketing authorisation number
3-5480-20


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                February 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>